Suppr超能文献

新型膜相关辅助因子 AuxA 和 AuxB 通过稳定脂磷壁酸来调节耐甲氧西林金黄色葡萄球菌的β-内酰胺类药物耐药性。

The Novel Membrane-Associated Auxiliary Factors AuxA and AuxB Modulate β-lactam Resistance in MRSA by stabilizing Lipoteichoic Acids.

机构信息

Department of Veterinary and Animal Sciences, University of Copenhagen, Denmark.

Lydia Becker Institute of Immunology and Inflammation, Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PT, United Kingdom.

出版信息

Int J Antimicrob Agents. 2021 Mar;57(3):106283. doi: 10.1016/j.ijantimicag.2021.106283. Epub 2021 Jan 24.

Abstract

A major determinant of β-lactam resistance in methicillin-resistant Staphylococcus aureus (MRSA) is the drug insensitive transpeptidase, PBP2a, encoded by mecA. Full expression of the resistance phenotype requires auxiliary factors. Two such factors, auxiliary factor A (auxA, SAUSA300_0980) and B (auxB, SAUSA300_1003), were identified in a screen against mutants with increased susceptibility to β-lactams in the MRSA strain, JE2. auxA and auxB encode transmembrane proteins, with AuxA predicted to be a transporter. Inactivation of auxA or auxB enhanced β-lactam susceptibility in community-, hospital- and livestock-associated MRSA strains without affecting PBP2a expression, peptidoglycan cross-linking or wall teichoic acid synthesis. Both mutants displayed increased susceptibility to inhibitors of lipoteichoic acid (LTA) synthesis and alanylation pathways and released LTA even in the absence of β-lactams. The β-lactam susceptibility of the aux mutants was suppressed by mutations inactivating gdpP, which was previously found to allow growth of mutants lacking the lipoteichoic synthase enzyme, LtaS. Using the Galleria mellonella infection model, enhanced survival of larvae inoculated with either auxA or auxB mutants was observed compared with the wild-type strain following treatment with amoxicillin. These results indicate that AuxA and AuxB are central for LTA stability and potential inhibitors can be tools to re-sensitize MRSA strains to β-lactams and combat MRSA infections.

摘要

耐甲氧西林金黄色葡萄球菌 (MRSA) 中β-内酰胺类药物耐药的一个主要决定因素是由 mecA 编码的药物不敏感转肽酶 PBP2a。耐药表型的完全表达需要辅助因子。在针对 MRSA 菌株中β-内酰胺类药物敏感性增加的突变体的筛选中,发现了两种这样的辅助因子,辅助因子 A (auxA,SAUSA300_0980) 和 B (auxB,SAUSA300_1003)。auxA 和 auxB 编码跨膜蛋白,AuxA 预测为转运蛋白。在不影响 PBP2a 表达、肽聚糖交联或壁磷壁酸合成的情况下,auxA 或 auxB 的失活增强了社区、医院和家畜相关 MRSA 菌株对β-内酰胺类药物的敏感性。两种突变体对脂磷壁酸 (LTA) 合成和丙氨酸化途径抑制剂的敏感性增加,即使没有β-内酰胺类药物,也会释放 LTA。aux 突变体的β-内酰胺类药物敏感性受到 gdpP 失活突变的抑制,先前发现 gdpP 允许缺乏脂磷壁酸合酶酶 LtaS 的突变体生长。使用家蚕感染模型,与野生型菌株相比,在用阿莫西林处理后,接种 auxA 或 auxB 突变体的幼虫的存活率提高。这些结果表明 AuxA 和 AuxB 是 LTA 稳定性的核心,潜在的抑制剂可以成为重新使 MRSA 菌株对β-内酰胺类药物敏感并对抗 MRSA 感染的工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验